Karyopharm Therapeutics Inc.
KPTI
$8.05
-$0.33-3.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -156.52% | -42.46% | -37.43% | 57.27% | 46.60% |
| Total Depreciation and Amortization | -12.94% | 6.55% | -3.90% | 2.46% | -35.85% |
| Total Amortization of Deferred Charges | 65.58% | 147.29% | 396.15% | 963.82% | 682.43% |
| Total Other Non-Cash Items | 241.91% | 83.36% | 56.69% | -549.22% | -426.34% |
| Change in Net Operating Assets | 9,461.59% | 254.13% | 3,470.34% | -13.27% | -100.96% |
| Cash from Operations | 40.88% | 25.70% | 21.02% | -4.43% | -37.49% |
| Capital Expenditure | -- | 127.18% | 127.18% | 127.18% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -54.63% | -50.68% | -39.72% | 42.11% | 1,104.22% |
| Cash from Investing | -54.57% | -50.54% | -39.54% | 42.64% | 1,102.43% |
| Total Debt Issued | -67.29% | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 555.03% | 0.00% | 0.00% | 29.18% | 29.18% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 85.01% | 100.00% | -307.24% | -- | -- |
| Cash from Financing | -27.85% | -97.49% | -97.49% | 3,605.16% | 3,605.16% |
| Foreign Exchange rate Adjustments | 281.82% | -105.10% | 190.00% | 300.00% | 67.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -119.99% | -222.94% | -1,511.25% | 114.28% | 111.50% |